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ABSTRACT 
Meloxicam is practically insoluble in water and its dissolution is the rate-limiting step for its absorption, which leads variable bioavailability. The aim of this investigation was 
to enhance the dissolution rate of Meloxicam by formation of microcrystals using solvent change method. Improved bioavailability is an added advantage for most of the poorly 
soluble drugs in water.  In recent years research work is concentrated on various methods to improve the solubility characteristics of poorly soluble drugs and crystallization 
phenomenon is one among them.  The solubility problem can be solved by changing the crystal habit of drug, which improves the solubility and dissolution. Crystallization is 
also a purification process to remove the impurities from pharmaceutical products by, recrystallization technique. So, in the present investigation an attempt has been made to 
improve the solubility characteristics of Meloxicam (NSAID’s) using crystallization method by solvent evaporation technique. To increase the therapeutic efficiency and quality 
of existing marketed dosage formulations. In this method, crystallization takes places mainly due to the removal of solvent by evaporation and reprecipitation in water in which 
drug is insoluble. The biphasic layer formed due to water immiscible solvent and is evaporated by maintaining the temperature above to corresponding boiling point of solvents. 
In our  work three immiscible  solvents, chloroform, ethyl acetate and dichloromethane used and  microcrystals prepared under  slow and turbulent  stirring  conditions. The 
precipitated crystals were filtered using whatmann paper and dried at 60° C for 1 hour. The formulated crystals of Meloxicam were subjected to various physico-chemical 
parameters like size distribution, shape and drug, solvent interactions with DSC, IR, XRD etc., and found to be smaller in size than pure and crystalline in nature with free from 
any interactions. For all the samples in-vitro drug release parameters studied U.S.P. XXIII dissolution rate test apparatus (Electrolab) employing paddle stirrer for one hour. In 
900 ml phosphate buffer (pH 7.4) and compared with pure drug samples. The microcrystals produced with 30% v/v chloroform, 30% v/v dichloromethane and 30% v/v ethyl 
acetate as solvents prepared under turbulent stirring conditions precipitated in water as crystallization media found to be best formulations for improved drug dissolution when 
compared to the pure drug for Meloxicam respectively.  The results thus conclusively proved that the method of precipitation by solvent evaporation technique can be used to 
produce microcrystals of poorly soluble non-steroidal anti-inflammatory drugs. 
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INTRODUCTION  
More  than  40%  of  active  substances  during  formulation 
development  by  the  pharmaceutical  industry  are  poorly  water 
soluble.  Poor  water  solubility,  which  is  associated  with  poor 
dissolution  characteristics.  Dissolution rate  in  the  gastro-intestinal 
tract is the rate limiting factor for the absorption of these drugs, and 
so they suffer from poor oral bioavailability. For BCS class II-drugs, 
the dissolution rate is the limiting factor for the drug absorption rate. 
An enhancement in the dissolution rate of these drugs can increase 
the blood-levels to a clinically suitable level. Several techniques are 
commonly used to improve dissolution and bioavailability of poorly 
water-soluble  drugs
1,2.Crystallization  is  the  spontaneous 
arrangement  of  the  particles  into  a  repetitive  orderly  array,  i.e., 
regular geometric patterns. Crystallization is a phenomenon in which 
solid particles formed by solidification under favorable conditions of 
a chemical element or a compound, whose boundary surfaces are 
planes symmetrically arranged at definite angles to one another in a 
definite  geometric  form.  In  the  matter,  particles  are  present 
randomly  due  to  thermal  agitation.  In  gases  the  disorderliness  is 
highest and in liquids it is moderate.  The liquids can solidify into 
crystalline forms, whenever attraction forces between particles are 
strong  enough to  overcome  the  disorderliness.  Crystallization  can 
proceed  directly  from  vapor  of  a  substance.    Examples  are  solid 
camphor from camphor vapor, solid iodine from iodine vapor.  Such 
a process is known as sublimation.  Crystals are commonly obtained 
from liquid state.  Example is salt from brine.  Crystallization deals 
with the later type, i.e., from solution to solid state. Crystallization 
differs  from  precipitation in  that the  product  is  deposited  from  a 
supersaturated  solution.    Precipitation  occurs  when  solutions  of 
materials  react  chemically  to  form  a  product,  which  is  sparingly 
soluble in the liquid and therefore deposits out. The polymorphic 
changes will have a definite influence on the solubility and thereby 
bioavailability of a particular compound due to structural differences 
resulting  from  different  arrangements  of  molecules  in  the  solid 
state
3,4. There are several methods of crystallization reported in the 
literature survey; aspirin microcrystal’s by spherical crystallization, 
Sulfaguanidine  microcrystal  by  microprecipitation  technique, 
Paracetamol microcrystals by solvent change method. The present 
work, is focused on the influence of polymorphism phenomenon on 
the  solubility  profile  of  meloxicam  which  belongs  to  sulfoanilide 
group,  a non-steroidal anti inflammatory drug
5,6. 
MATERIAL AND METHODS 
Meloxicam  was  a  gift  sample  from  Unichem  Lab.  Pvt.  Ltd., 
Mumbai. Chloroform, ethyl acetate and dichloromethane and other 
chemicals used were of analytical grade. 
Preparation of microcrystals 
Solvent evaporation technique has been used in the present study to 
prepare  microcrystals.  In  this  method,  crystallization  takes  place 
mainly  due  to  the  removal  of  solvent  by  evaporation  and 
precipitation  in  water  in  which  drug  is  insoluble.  The  basic 
procedure employed for preparing microcrystals of drugs consists of 
the following steps. Preparation of drug solution in different water 
immiscible  solvents  i.e.,  chloroform,  ethyl  acetate  and 
dichloromethane in 10 ml, 20 ml and 30 ml, respectively with 1g. of 
drug.  The  above  prepared  drug  solution  was  added  drop-wise  to 
water  i.e.,  10%,  20%  and  30%  v/v  in  a  250  ml.  beaker  with 
continuous stirring (slow and turbulent). The biphasic layer formed 
due to water immiscible solvent is evaporated by maintaining the 
temperature corresponding to their boiling point. Microprecipitation 
takes place due to the evaporation of water immiscible solvents and 
reprecipitation  of  drug  in  water.  The  precipitated  crystals  were 
filtered using Whatmann filter paper and dried at 60° C for 1 hour
7,8. 
Characterization 
Size and Size Distribution: There are many methods used for the 
determination  of  particle  size  of  pharmaceutical  solids.    As  the 
crystals obtained in the present work were small and belong to sub-Nagoba Shivappa N et al. IRJP 2011, 2 (11), 136-139 
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sieve range in their size, microscopic method was used to determine 
their size, projection microscope Sipcon SP585/SP585A was used to 
measure  the  diameter  of  not  less  than  400  particles  from  each 
batch
9,10. 
Mean Volume Surface Diameter (dvs): The values of mean volume 
surface  diameter  (dvs)  was  computed  by  using  Hatch-Chotes 
equation,  as  the  sample  were  found  to  obey  log  normal 
distribution
11,12.  The equation used to calculated the mean volume 
surface diameter (dvs). 
Determination of Specific Surface Area (Sw): It is defined as the 
surface  area  per  unit  weight.    This  was  determined  by  using  the 
formula: 
Sw = 
vs d ´ r
6
 
Where,  dvs= mean volume surface diameter in microns. 
r = crystal density in gm/cc. 
Density of the crystal samples: The density of various batches of 
microcrystals  were  determined  in  water.    The  density  of  these 
samples are less than the water.  The drug particles were found to 
float on the surface when added to water.  In order to find the up 
thrust (apparent loss of weight) sample is completely immersed in 
water, a metal piece sufficiently heavy to sink the solid has been 
used to find out the density of samples
13. 
Photomicrographs:  The  shape  of  micro  precipitated  crystals 
produced in different solvents by solvent evaporation technique in 
different magnifications (10x, 20x and 30x) was analyzed by using 
Nickon research microscope HFX-DX.  This was carried out in the 
Department of Botany at Gulbarga University, Gulbarga. 
Infrared  Spectral  Analysis:  Infrared  spectra  original  drug  and 
microcrystals  prepared  from  different  solvents  were  obtained  by 
KBr  pellet  method  using  Perkin  Elmer  FTIR  series  model  1615 
spectrometer in order to rule out drug solvent interaction occurring 
during  the  crystallization  process.  To  assess  the  purity  of 
microcrystals  in  different  solvent  systems,  their  infrared  spectra 
were taken and compared with those of that are obtained by original 
drug sample, by pellet KBR method using FTIR 1615 Perkin Elmer 
due to lack of facility in the college, the samples were analyzed at 
Sipra Lab, Hyderabad. 
X-ray Powder Diffraction:  Powder X-ray diffraction is both rapid 
and relatively simple method for the detection of change in form.  
The amorphous materials do not show any pattern and is unique to 
each polymorphic form.  XRD 6000 of Shimadzu, Japan was used to 
obtain  X-ray  powder  diffraction  patterns  for  original  sample 
microcrystals in different solvents.  This work was also carried out 
at Common Facility Centre, Shivaji University, Kolhapur due to lack 
of facilities in our institution. 
Differential Scanning Calorimetry Analysis (DSC):  In DSC a test 
sample  and  an  inert  reference  material  (alumina)  undergo  a 
controlled heating program.  If the sample undergoes any physical or 
chemical  change  than  the  difference  DT  will  occur  between  the 
sample and reference material.  The melting characteristics as well 
as the incidence of any interaction between and different solvents 
during  recrystallization  by  solvent  evaporation  method  were 
determined by carrying out differential scanning calorimetry on the 
respective crystalline samples i.e., original drug and microcrystals.  
DSC analysis were carried on Pyris-6 Perkin Elmer thermal analyzer 
at a heating rate of 5° C / min. in the range of 50-200°C in the 
nitrogen atmosphere.  This was also carried out at Common Facility 
Centre, Shivaji University, Kolhapur due to lack of facilities in our 
institution. 
 
 
In vitro Dissolution Studies 
Dissolution of drug microcrystals were studied using U.S.P. XXIII 
dissolution rate test apparatus (Electrolab) employing paddle stirrer. 
The in-vitro drug dissolution studies were carried out for 60 minutes 
In 900 ml phosphate buffer (pH 7.4) at 37
0C. The stirrer speed was 
fixed at 50 rpm throughout the dissolution period. A quantity of 100 
mg of drug microcrysals was taken in muslin bag and tied to the 
paddle. The samples were withdrawn at intervals of 10 minutes and 
analyzed  for  drug  content  at  364  nm  using  shimadzu  UV-visible 
spectrophotometer
14. 
RESULTS  
The average diameter value of Meloxicam original crystals found to 
be 34.25 microns, whereas its microcrystals prepared in 30% v/v of 
Chloroform in turbulent stirring conditions were found to be 26.11 
microns. The surface area (Sw) of Meloxicam original crystals was 
found to be 5.91 x 10
3 gm/cm², whereas the microcrystals prepared 
in  30%  v/v  of  Chloroform  in  turbulent  stirring  conditions  were 
found to be 5.51 x 10
3 gm/cm². Photomicrographs of microcrystals 
of drug produced by solvent evaporation method showed  reduced 
size in shape when compared to pure drug crystals.  The density of 
original drug was found to be 0.232 gm/cc, and microcrystals was 
found to be 0.225 gm/cc.  The infrared spectra of microcrystals of 
drug with different solvents was almost similar to that of spectra of 
pure drug indicating that there is no interaction between drug and 
solvent. The X-ray diffractograms of pure drug, and microcrystals of 
Meloxicam  in  Chloroform  solvent.    Revealed  that  maximum 
intensity of the peak of pure drug found to be 357.21 and number of 
peaks 38, whereas for form of the maximum intensity of peak found 
to be 422.10 and total number of peaks 43.  This clearly indicates the 
purity  of  dosage  form.  Differential  Scanning  Calorimetry  (DSC) 
studies of original drug of Meloxicam showed a sharp endothermic 
peak  with highest  peak  area  at a melting  point  of  267.45°C,  and 
microcrystals of Meloxicam produced in of Chloroform solvent has 
exhibited  endothermic  peaks  with  comparatively  reduced  areas  at 
lower  melting  point  of  265.89°C.    The  crystals,  produced  in  of 
Chloroform solvent system gave lower area of endothermic peak.  
So it can be concluded from the results of DSC that the solvents 
used  for  recrystallization  have  a  marked  effect  on  the  melting 
characteristics  of  the  crystals.  In-vitro  drug  dissolution  of 
Meloxicam microcrystals with 30% Chloroform showed promising 
results in 60 min. It showed 98.77% drug release in turbulent stirring 
condition.  Among  several  experiments  conducted  with  different 
solvents and varied stirring conditions, the microcrystals produced 
with  30%  v/v  Chloroform  as  solvent  prepared  under  turbulent 
stirring  condition  precipitated  in  water  as  crystallization  media 
found to be best formulation for improved drug dissolution when 
compared to the pure drug.  The results thus conclusively proved 
that the method of precipitation by solvent evaporation technique 
can be used to produce microcrystals of poorly soluble non-steroidal 
anti-inflammatory drugs, which can be formulated into quick acting 
dosage  forms  for  acute  arthritic  conditions  and  musculo-skeletal 
disorders. 
DISCUSSION 
Among several experiments conducted with different solvents and 
varied stirring conditions, the microcrystals produced with 30% v/v 
Chloroform  as solvent prepared under turbulent stirring condition 
precipitated  in  water  as  crystallization  media  found  to  be  best 
formulation  for  improved  drug  dissolution  when  compared  to  the 
pure drug. Thus the results proved that the method of precipitation 
by  solvent  evaporation  technique  can  be  used  to  produce 
microcrystals  of  poorly  soluble  non-steroidal  anti-inflammatory 
drugs especially drugs, which can be formulated into quick acting Nagoba Shivappa N et al. IRJP 2011, 2 (11), 136-139 
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dosage  form  for  acute  arthritic  condition  and  musculo-skeletal 
disorders. 
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Table 1: Statistical Significance data of Prepared Meloxicam microcrystals 
 
Sr.No. 
Formulation 
 
dg  6g  dav  SD  CV%  r  dvs  SW 
1 
 
Pure Drug 
15.48  1.90  34.25  21.86  63.82  0.232  43.71  5.91×10
3 gm/cm
2 
 
2  Meloxicam 
microcrystals  14.12  2.01  26.11  14.56  55.76  0.225  48.31  5.51×10
3 gm/cm
2 
 
dg = Geometric mean diameter in microns.    6g = Geometric standard deviation in microns. 
dav = Averagediameter in microns.    SD = Standard Deviation. 
CV = Coefficient variance in percentage.    r = Density in gm/cc. 
dvs = Mean  volume surface diameter in micron.  SW = Surface area by weight. 
 
Table 2: In vitro Dissolution of Meloxicam in pure form and Microcrystals prepared using Dichloromethane, Ethyl Acetate and Chloroform Solvent at Turbulent 
stirring condition in pH 7.4 Phosphate buffer 
Time 
(min) 
Pure 
Drug 
Cumulative % drug release 
DM1  DM2  DM3  EA1  EA2  EA3  CF1  CF2  CF3 
10  13.35  15.55  20.22  28.70  20.58  26.81  29.32  23.55  27.62  34.54 
20  29.25  31.77  37.18  41.33  38.99  44.80  41.64  35.43  38.58  43.66 
30  37.93  44.68  49.99  51.56  48.85  54.77  53.83  48.50  52.09  56.23 
40  48.85  56.89  61.65  60.88  57.76  63.48  64.84  56.77  63.92  70.44 
50  58.65  63.43  69.76  71.91  66.87  74.20  75.15  71.34  74.76  82.14 
60  71.05  75.87  80.00  84.86  79.44  83.51  87.65  82.90  87.33  98.77 
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CF1-Meloxicam microcrystals with 10% v/v chloroform    EA1-Meloxicam microcrystals  with 10% v/v Ethyl acetate 
CF2-Meloxicam microcrystals with 20% v/v chloroform   EA2-Meloxicam microcrystals with 20% v/v  Ethyl acetate 
CF3-Meloxicam microcrystals with 30% v/v chloroform EA3-Meloxicam microcrystals  with 30% v/v Ethyl acetate 
DM1-Meloxicam microcrystals with 10% v/v Dichloromethane 
DM2-Meloxicam microcrystals with 20% v/v Dichloromethane 
DM3-Meloxicam microcrystals with 30% v/v Dichloromethane 
Figure 1: In vitro Dissolution of Meloxicam in pure form and Microcrystals prepared using Dichloromethane, Ethyl Acetate and Chloroform Solvent at Turbulent 
stirring condition in pH 7.4 Phosphate buffer Nagoba Shivappa N et al. IRJP 2011, 2 (11), 136-139 
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Pure drug       Microcrystals prepared 
Figure 2: Photomicrograph of Meloxicam 
 
 
Figure 3: FTIR Spectrum of Meloxicam 
 
 
Figure 4: Differential Scanning Calorimetry of Piroxicam 
 
 
Figure 5:  X-Ray diffraction analysis of Piroxicam 
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